

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHARMACY PHARMACEUTICAL CO., LTD.**

### **創美藥業股份有限公司**

*(a joint stock limited liability company established in the People's Republic of China)*

**(Stock code: 2289)**

### **POSITIVE PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Law of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on the preliminary review of the management accounts of the Group for the year ended 31 December 2016 and the information currently available to the Board, the Group is expected to record a growth of not less than 110% in the Group's profit attributable to the owners of the Company for the year ended 31 December 2016 as compared with that of the year ended 31 December 2015.

The information contained in this announcement is only based on a preliminary review of the management accounts of the Group for the year ended 31 December 2016 and the information currently available to the Board. Such accounts have not been audited or reviewed by the Company's auditors or the audit committee of the Board.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

This announcement is made by Charmacy Pharmaceutical Co., Ltd. (the "**Company**", together with its subsidiary shall be referred to as the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the management accounts of the Group for the year ended 31 December 2016 and the information currently available to the Board, the Group is expected to record a growth of not less than 110% in the Group’s profit attributable to the owners of the Company for the year ended 31 December 2016 as compared with that of the year ended 31 December 2015 (audited profit attributable to the owners of the Company for the year ended 31 December 2015 amounted to approximately RMB26.36 million). The anticipated substantial increase is mainly due to (i) increases in sales of products and gross profit of the Group; and (ii) there is no listing expense for the year ended 31 December 2016 as compared with that of the year ended 31 December 2015.

The Company is still in the process of finalizing the Group’s annual results for the year ended 31 December 2016. The information contained in this announcement is only the preliminary assessment according to the management accounts of the Group and the information currently available to the Board, which have not been audited and reviewed by the Company’s auditors or the audit committee of the Board. Financial information and other details of the Group will be disclosed in the announcement of annual results of the Group for the year ended 31 December 2016 which is expected to be announced in March 2017.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yao Chuanglong**  
*Chairman*

Hong Kong, 24 January 2017

*As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan, Mr. Fan Jianbo and Mr. Lin Zhixiong; the non-executive director of the Company is Ms. You Zeyan; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).*